|
Feb 21
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Feb 19
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 18
|
Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
|
|
Feb 15
|
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
|
|
Feb 14
|
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call
|
|
Feb 14
|
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
|
|
Feb 14
|
Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
|
|
Feb 13
|
Ultragenyx: Q4 Earnings Snapshot
|
|
Feb 13
|
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
|
|
Feb 6
|
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
|
|
Feb 6
|
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
|
|
Feb 6
|
Ultragenyx announces new data on UX111 AV gene therapy
|
|
Feb 5
|
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reduc...
|